Have any Questions? +01 123 444 555
DE

Tecemotide (L-BLP25) or emepepimut

L-BLP25 is an investigational MUC1 antigen-specific cancer immunotherapy that is designed to stimulate the body’s immune system to identify and target cells expressing the cell surface glycoprotein MUC1. MUC1 is expressed in many cancers, such as non-small cell lung cancer (NSCLC), and has multiple roles in promoting tumor growth and survival. L-BLP25 was being investigated in the Phase III START trial and is currently being investigated in the INSPIRE trial, both for the treatment of unresectable stage III NSCLC

According to the NCI website, emepepimut-SA is a liposome-encapsulated peptide vaccine consisting of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic activity. Check for active clinical trials using this agent. (NCI Thesaurus)

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to National Cancer Institute

Notable treatment effects were observed for L-BLP25 in certain subgroups in the START study

MUC1

 

Alle Wirkstoffe

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Kongressorganisatoren beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weitere Finanzierungsquellen werden bei den jeweiligen Berichten aufgeführt. Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2022. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close